Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious 24 disease localized to China, Japan, and Korea that is characterized by severe hemorrhage and a 25 high fatality rate. Currently, no specific vaccine or treatment has been approved for this 26 disease. To develop a therapeutic agent for SFTS, we isolated antibodies from a phage-27 displayed antibody library that was constructed from a patient who recovered from SFTS 28 virus (SFTSV) infection. One antibody, designated as Ab10, was reactive to the Gn envelope 29 glycoprotein of SFTSV and protected host cells and A129 mice from infection in both in 30 vitro and in vivo experiments. Notably, Ab10 protected 80% of mice, even when injected 5 31 days after inoculation with a lethal dose of SFTSV. Using cross-linker assisted mass 32 spectrometry and alanine scanning, we located the non-linear epitope of Ab10 on the Gn 33 glycoprotein domain II and an unstructured stem region, suggesting that Ab10 may inhibit a 34 conformational alteration that is critical for cell membrane fusion between the virus and host 35 cell. Ab10 reacted to recombinant Gn glycoprotein in Gangwon/Korea/2012, HB28, and SD4 36 strains. Additionally, based on its epitope, we predict that Ab10 binds the Gn glycoprotein in 37 247 of 272 reported SFTSV isolates previously reported. Together, these data suggest that 38 Ab10 has potential to be developed into a therapeutic agent that could protect against more 39 than 90% of reported SFTSV isolates. 40 41 Author summary 42 Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious 43 disease localized to China, Japan, and Korea. This tick-borne virus has infected more than 44 5,000 humans with a 6.4% to 20.9% fatality rate. Currently, there are no prophylactic or 45 therapeutic measures against this virus. Historically, antibodies from patients who recovered 46 from viral infection have been used to treat new patients. Until now, one recombinant 47 monoclonal antibody was approved for the prophylaxis of respiratory syntial virus infection. 48 We selected 10 antibodies from a patient who recovered from SFTS and found that one 49 antibody potently inhibited SFTS viral infection in both test tube and animal studies. We 50 determined the binding site of this antibody to SFTS virus, which allowed us to predict that 51 this antibody could bind 247 out of 272 SFTS virus isolates reported up to now. We 52 anticipate that this antibody could be developed into a therapeutic measure against SFTS. 53 54 Introduction 55 Since its isolation as a novel virus in 2011, cases of the acute infectious disease called 56 severe fever with thrombocytopenia syndrome (SFTS)[1] have risen rapidly in China, Japan, 57 and Korea, posing a risk to public health and increasing the fear of ticks that transmit the 58 deadly SFTS virus (SFTSV). From 2011 to 2016, this emerging tick-borne virus infected 59 5,360 people in China with an average case fatality rate of 6.40%[2]. After initial reports in 60 2013 of sporadic SFTS cases in South Korea[3] and Japan[4], South Korea reported 605 61 cases with an average case fatality of 20.9%[5] and Japan reported 310 cases with an average 62 fatality of 19.4%[6] from 2013 to 2017. 63 Ticks such as Haemaphysalis longicornis and Rhipicephalus microplus are implicated as the 64 prominent vectors for transmitting SFTSV[7]. With regards to SFTSV hosts, various 65 vertebrate species are considered to have been infected, as evidenced by high SFTSV 66 seroprevalence in domestic animals in SFTS endemic regions[8,9]. Additionally, reported 67 cases of human-to-human transmission through contact with blood or body fluid, including 68 infections in healthcare workers from patients, pose a further threat to the public[10,11]. 69 Furthermore, the discovery of H. longicornis tick in the United States indicates the possibility 70 that SFTSV could spread to other continents, highlighting the need to prevent disease 71 transmission[12]. 72 SFTSV is a single-stranded negative-sense tripartite RNA virus that is classified as a member 73 of the Phlebovirus genus, Phenuiviridae family, and Bunyaviriales order. The genome of 74 SFTSV is comprised of L, M, and S segments, which encode RNA-dependent RNA 75 polymerase (L segment), envelope Gn glycoprotein (M segment), envelope Gc glycoprotein 76 (M segment) , nucleoprotein, (S gement) and nonstructural proteins (S segment) [13]. A 77 phylogenetic analysis based on genome sequences of SFTSV isolates found substantial 78 genetic diversity and accumulated mutations, suggesting that SFTSV has existed for decades 79 at minimum[14,15]. However, the difference in virulence between these SFTSV sub-lineages 80 has yet to be determined. 81 The major clinical features of SFTS include high fever, fatigue, malaise, anorexia, nausea, 82 vomiting, diarrhea, thrombocytopenia, leukocytopenia, and abdominal pain[16,17]. In severe 83 cases, SFTS can include central nervous system manifestations, hemorrhagic signs, and 84 multiple organ dysfunction, which can lead to death[18-21]. No vaccines or therapeutics 85 specific for SFTS have been approved for human use. Recently, a Phase 3 clinical trial of 86 favipiravir (Avigan ® ), an drug approved for the treatment of influenza virus infection in 87 Japan, was initiated to expand its indication to SFTS treatment[22]. Monoclonal antibodies or 88 convalescent sera from SFTS patients were tested to identify potential therapeutic 89 intervention targets, resulting in the identification of SFTSV glycoproteins as molecules 90 required for host cell entry [23,24] and also as critical targets for virus neutralization through 91 the development of humoral immunity. However, generating an antibody for these targets in 92 infected humans was found to be rare, due to the presence of immunodominant decoy 93 epitopes in the nucleoprotein [25], which is a common phenomenon in a pathogenic virus-94 infected host [26]. But in animal models, the protective effect of human convalescent sera was
shown, suggesting that antibody therapy is possible [27] . Thus far, MAb4-5 is the only human 96 neutralizing monoclonal antibody reported, and it was developed using a combinatorial 97 human antibody library from five patients [28] . MAb4-5 binds to domain III of SFTSV Gn 98 glycoprotein [29] . The neutralizing effect of MAb4-5 has been shown only in in vitro, and its 99 in vivo efficacy remains to be shown. 100 In this study, we constructed an antibody library from a patient who recovered from SFTS, 101 and selected antibodies against the Gn and Gc glycoproteins. Among these antibodies, Ab10 102 bound to Gn glycoprotein and showed a potent neutralizing effect both in vitro and in vivo. In 103 addition, we characterized the conformational epitope of Ab10 using crosslinking coupled 104 mass spectrometry and by testing its reactivity to alanine mutants, which allowed us to 105 estimate the strain coverage of Ab10.
107
Results 108 Anti-Gn/Gc glycoprotein antibodies were selected from an antibody library generated 109 from a convalescent SFTS patient 110 In human embryonic kidney (HEK) 293F cell, we produced Gn and Gc glycoproteins 111 fused with a crystallizable fragment of the human immunoglobulin (Ig) heavy chain constant 112 region (Gn-Fc and Gc-Fc) or those fused with the human Ig kappa light chain constant region 113 (Gn-Cκ and Gc-Cκ) and then purified the proteins. We constructed the phage-displayed 114 single-chain variable fragment (scFv) antibody library with a complexity of 1.3  10 9 using 115 peripheral blood mononuclear cells isolated from a patient who had recovered from SFTS. 116 The library was subjected to four rounds of biopanning against either the recombinant Gn-Fc 117 or the Gc-Fc fusion proteins conjugated to paramagnetic beads. We randomly selected 118 phagemid clones from the output titer plate from the last round of biopanning and subjected 119 these clones to phage enzyme-linked immunosorbent assay (ELISA). To minimize the 120 number of clones reactive to the Fc portion of fusion proteins, Gn-Cκ and Gc-Cκ were used 121 as antigens. Positive clones were selected and subjected to Sanger sequencing to determine 122 the scFv nucleotide sequence. We identified five clones reactive to Gn and five clones 123 reactive to Gc. All of these scFv clones were expressed as a scFv antibody fused with Fc 124 (scFv-Fc) in HEK293F cell and purified using affinity chromatography. 
133
In an immunofluorescence assay (IFA) using Vero cells and an anti-Gn antibody, we 134 determined the proportion of Gn glycoprotein producing cells, which were infected with 135 SFTSV, to measure the neutralizing potency of Ab10. Only 5.6 ± 2.8% (mean ± s.d.) of Vero 136 cells produced Gn glycoprotein when Ab10 was treated at a concentration of 50 μg/ml (956 137 nM) ( Fig 1) . Ab10 also showed a dose-dependent protective effect (S3 Fig 173 and Japan. We successfully overexpressed Gn glycoprotein from HB29 and SD4 as a Fc 174 fusion protein and subjected these proteins to ELISA. Ab10 IgG 1 successfully bound to Gn 175 glycoproteins from the HB29 and SD4 strains in a dose-dependent manner, at concentrations 176 ranging from 10 pM to 1 nM ( Fig 4A) . Further, the amount of antibody bound to the HB29 177 and SD4 Gn glycoproteins coated on the ELISA plate was higher than that of the 178 Gangwon/Korea/2012 glycoproteins, at most of the tested concentrations. We also found that 179 Mab4-5 was reactive to Gn glycoprotein from the HB29 and SD4 strains ( Fig 4B) .
180
We used surface plasmon resonance analysis to determine the kinetics of Ab10 181 binding to the Gn glycoprotein of Gangwon/Korea/2012. Ab10 bound to Gn glycoprotein 182 with an equilibrium dissociation constant (K D ) of 104 pM and found an association rate (K on ) 183 of 7.4  10 5 M -1 s -1 and a dissociation rate (K off ) of 7.7  10 -5 s -1 ( Fig 4C) . 
185 Ab10 binds to a non-linear epitope on domain II and the stem region of the

259
The mechanisms of antibody inhibition of viral replication inside host cells have been 260 studied extensively, especially in the case of influenza virus. The most-widely known 261 mechanism is for an antibody to bind the portion of virus that interacts with the host cell 262 receptor, thereby blocking the interaction between the virus and the host cell [52] . Another 263 group of antibodies was reported to bind the stem region of influenza hemagglutinin that is 264 critical for conformational rearrangements that occur during membrane fusion [53] [54] [55] . This 265 mechanism has more potential to be utilized for clinical development, because the stem 266 region has fewer mutations than the receptor binding site. Additionally, several groups, 267 including ours, have elucidated unconventional virus neutralizing mechanisms that affect the 268 infection steps that occur after membrane fusion [56, 57] .
269
In our crosslinking coupled mass spectrometry and alanine mutant studies, the Ab10 
279
In conclusion, Ab10 is a monoclonal antibody that has shown therapeutic efficacy in a 280 mouse SFTSV infection model. Although the neutralization efficacy of Ab10 was only tested 281 in the Gangwon/Korea/2012 strain that was cultured in Vero cells, we confirmed its binding 282 capability to recombinant SFTSV Gn in the HB29 and SD4 strains, which are both from 283 China. According to the epitope revealed in this study, Ab10 is estimated to interact with the 284 majority of SFTSV isolates currently reported. Based on these results, we believe that Ab10 285 has sufficient potential to be developed as a prophylactic and therapeutic agent for a broad 286 variety of SFTS isolates. 
